entertainment -WSS

entertainment

author：fashion 2025-09-30 08:51:49 - browse：42

Chief executive officer of Sanofi Paul Hudson, wearing glasses, speaks into a mic — pharma coverage from STAT — Sanofi CEO Paul Hudson Carolyn Kaster/AP

LONDON — Sanofi CEO Paul Hudson on Wednesday defended his company’s recent moves to abandon future profit guidance and up its investment in its own research programs, arguing that the dramatically negative market response didn’t reflect the potential rewards that could stem from the plan.

“Would I have liked the stock market reaction to be more generous? Of course,” Hudson said at a Financial Times event in London. “But this is a long-term game, and if you’re trying to deliver long-term value, you try not to make too many short-term decisions.”

Sanofi unveiled its R&D plans late last month as it announced its third-quarter performance and said that it was spinning out its consumer health division. As the company said it was going to spend more money on research, it also withdrew earnings outlooks for 2025. Company executives have argued that this was the moment — when Sanofi has a strong pipeline and isn’t facing patent expirations for years — to increase its R&D resources, even at the expense of short-term profits.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： When is a doctor not a doctor? Try when patients address women doctors

focus

leisure time

WSS

The debate over Covid

Grail is spending more than ever lobbying Congress

Duchenne patients, backed by ‘dark money’ group, to debate drug prices

These geoengineering technologies could help combat the climate crisis, scientists say

Grail is spending more than ever lobbying Congress

EU fines Illumina $475 million over Grail acquisition

focus

entertainment

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

EU fines Illumina $475 million over Grail acquisition

BioMarin wins approval for gene therapy to treat hemophilia A

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

Hepatitis C has a cure — but many Americans still lack access to it

Va. Republicans encourage early voting, a target of Trump's, ahead of fall elections

Hollywood unions extend contract negotiations for actors

Bacterial infection may be ‘key event’ in endometriosis, study says

Apple is now the first public company to be valued at $3 trillion

Digital health funding stays low as a new reality sets in

hotspot

China sends large group of warplanes, navy ships towards Taiwan in forceful display

Inside the fall of star MIT scientist David Sabatini

Antibody drugs appear effective. Now can we make enough of them?

Make 'food is medicine' a key part of White House nutrition meeting

Companies helping big Covid

4 killed, 7 hurt in mass shooting at July 4 block party in Louisiana; no arrests made

Wikipedia

focus

leisure time

focus